Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition - Fierce Biotech

Rapport reported positive results from a phase 2 trial in bipolar disorder, drawing analyst recognition, though the trial did not meet its original goal. The brief provides no drug name, trial name, sample size, effect size, or safety data, so the magnitude of the results cannot be further assessed.